Clinical Trial News and Research

RSS

Ohio State's novel DHODH inhibitor enters first human trials

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient's bedside as part of a clinical trial.

17 Sep 2024

Postsurgical treatment with pembrolizumab doubles cancer-free time for bladder cancer patients

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder.

17 Sep 2024

Study shows no increase in depression after mild TBI in adolescents

With about 214,110 traumatic brain injuries (TBIs) and over 69,000 TBI-related deaths in 2021 according to the Centers for Disease Control and Prevention (CDC), understanding the physical and mental consequences of TBI is critical for study.

16 Sep 2024

ESMO 2024: Promising results in immunotherapy and antibody drug conjugates for gynecological cancers

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found 'promising' antitumor activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.

16 Sep 2024

New microscopy technique detects early Parkinson's disease indicators

Researchers at Tel Aviv University cooperated with three major Israeli medical centers to develop a new method for detecting protein aggregation in cells – a hallmark of Parkinson's disease.

16 Sep 2024

High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer

A double-blind randomized phase 3 clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition of high-dose vitamin D3 to standard treatment for patients with untreated metastatic colorectal cancer.

16 Sep 2024

Antibody-drug conjugate shows promise in treating ovarian and endometrial cancers

14 Sep 2024

New cancer drug shows encouraging results in Phase I/II trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

14 Sep 2024

New drug shows strong activity against brain metastases in HER2-positive breast cancer

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer.

13 Sep 2024

Breakthrough study sheds light on mechanisms behind the spread of gastric cancer to the peritoneum

Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to 770,000 deaths each year.

13 Sep 2024

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.

13 Sep 2024

Cannabidiol shows promise in treating cognitive disorders

Research reviews the therapeutic potential of cannabidiol (CBD) in treating cognitive impairments, highlighting positive effects in some trials while emphasizing the need for more comprehensive studies.

12 Sep 2024

New vaccine candidate shows promise for protecting against Lassa fever

Researchers from Thomas Jefferson University and the University of Maryland Baltimore, in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Geneva Foundation, have developed a promising new vaccine candidate that protects against Lassa fever.

12 Sep 2024

Duffy-null phenotype may lead to unfair exclusion from cancer drug trials

Many clinical trials of new cancer drugs may be inappropriately excluding some people with "Duffy-null phenotype," a trait found predominantly in people of African or Middle Eastern descent, researchers at Dana-Farber Cancer Institute and Queen Mary University of London report in a new study.

12 Sep 2024

Laughter exercise could be an initial treatment for relieving dry eye disease symptoms

Laughter may be as effective as eye drops in improving symptoms of dry eye disease, finds a clinical trial from China published by The BMJ today.

11 Sep 2024

New ultrasound technology provides effective treatment for urinary stones

A noninvasive ultrasound technology called Break Wave™ lithotripsy (BWL) offers a safe and effective new option for treatment of urinary stones, reports a clinical trial in the October issue of The Journal of Urology, an Official Journal of the American Urological Association (AUA).

11 Sep 2024

Telisotuzumab vedotin shows promising results in asian patients with c-Met overexpressing NSCLC

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer's 2024 World Conference on Lung Cancer.

11 Sep 2024

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.

11 Sep 2024

Study shows delayed feedback enhances learning in traumatic brain injury

Kessler Foundation researchers have published a novel study exploring the effects of delayed feedback on learning in individuals with moderate-to-severe traumatic brain injury (TBI).

11 Sep 2024

Taletrectinib shows high response rates and safety in ROS1+ lung cancer patients

The ROS1 tyrosine kinase inhibitor (TKI) taletrectinib demonstrated high overall and intracranial responses, and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC).

11 Sep 2024

Clinical Trial News and Research

Ohio State's novel DHODH inhibitor enters first human trials

Postsurgical treatment with pembrolizumab doubles cancer-free time for bladder cancer patients

Study shows no increase in depression after mild TBI in adolescents

ESMO 2024: Promising results in immunotherapy and antibody drug conjugates for gynecological cancers

New microscopy technique detects early Parkinson's disease indicators

High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer

Antibody-drug conjugate shows promise in treating ovarian and endometrial cancers

New cancer drug shows encouraging results in Phase I/II trial

New drug shows strong activity against brain metastases in HER2-positive breast cancer

Breakthrough study sheds light on mechanisms behind the spread of gastric cancer to the peritoneum

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

Cannabidiol shows promise in treating cognitive disorders

New vaccine candidate shows promise for protecting against Lassa fever

Duffy-null phenotype may lead to unfair exclusion from cancer drug trials

Laughter exercise could be an initial treatment for relieving dry eye disease symptoms

New ultrasound technology provides effective treatment for urinary stones

Telisotuzumab vedotin shows promising results in asian patients with c-Met overexpressing NSCLC

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

Study shows delayed feedback enhances learning in traumatic brain injury

Taletrectinib shows high response rates and safety in ROS1+ lung cancer patients

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer